Sotoraxibu Lao ASEAN pharmaceutical generic drug is on the market!

Sotorasib is a new type of anti-cancer drug that is a KRAS G12C inhibitor. KRAS G12C is a gene mutation that is common in a variety of cancers, especially in non-small cell lung cancer (NSCLC). Sotorasiib was developed to target this specific genetic mutation and provide new treatment options for patients suffering from the corresponding cancer.

The original drug of sotorasibu has not yet been launched in China, so patients cannot purchase it domestically and need to purchase sotorasibu through overseas channels. The price of the original version of sotorasibu in Hong Kong, China, with the specifications of 120mg*240 tablets, is around 8 million, and the price of the European version of the original drug with the same specifications is around 4 million, which is relatively expensive. The cheaper ones are the generic drugs marketed abroad. For example, the price of generic drugs in Laos and Bangladesh is around two to three thousand yuan. The price is relatively cheap, and the ingredients of foreign generic drugs are basically the same as the original drugs. Among them, the Laos-ASEAN version of generic drug specifications120mg*120 tablets costs around 5,000.

The mechanism of action of this drug is to block the abnormal signaling pathways in cancer cells by inhibiting the KRAS G12C mutant, thereby preventing the growth and spread of cancer cells. Because of its high selectivity for specific mutations, sotoracib provides patients with a more personalized and precise treatment plan.

Clinical trial results of sotoraxib showed that the drug showed significant efficacy in some patients with KRAS G12Cmutated NSCLC, providing hope for this urgent medical problem. This innovative drug has injected new vitality into the field of cancer treatment, providing a first-line treatment option for patients who have failed to respond satisfactorily to traditional treatments.